Savara (SVRA) Total Non-Current Liabilities (2016 - 2025)
Savara (SVRA) reported Total Non-Current Liabilities of $50.3 million for Q4 2025, up 21.67% year-over-year from $41.3 million in Q4 2024, and up 8.09% quarter-over-quarter from $46.5 million in Q3 2025.
Savara (SVRA) Total Non-Current Liabilities (2016 - 2025) Analysis & Trends
Savara (SVRA) has 10 years of Total Non-Current Liabilities data on file, last reported at $50.3 million in Q4 2025.
- Total Non-Current Liabilities for Q4 2025 came in at $50.3 million, up 21.67% year-over-year; the trailing twelve-month figure through Dec 2025 was $50.3 million (up 21.67% YoY), and the FY2025 annual result was $50.3 million, up 21.67% from the prior year.
- Total Non-Current Liabilities improved to $50.3 million in Q4 2025 per SVRA's latest filing, from $46.5 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $50.3 million in Q4 2025 and troughed at $29.6 million in Q1 2022.
- A 5-year average of $36.1 million and a median of $33.8 million in 2021 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2021 and 2022: Total Non-Current Liabilities rose 21.73% in 2021, then declined 8.69% in 2022.
- A 5-year view of Total Non-Current Liabilities shows it stood at $32.0 million in 2021, then fell by 0.12% to $31.9 million in 2022, then grew by 15.65% to $36.9 million in 2023, then grew by 11.9% to $41.3 million in 2024, then climbed by 21.67% to $50.3 million in 2025.
- Business Quant data shows SVRA's Total Non-Current Liabilities at $50.3 million in Q4 2025, $46.5 million in Q3 2025, and $43.3 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 50.30 Mn |
| Sep 30, 2025 | 46.54 Mn |
| Jun 30, 2025 | 43.28 Mn |
| Mar 31, 2025 | 41.42 Mn |
| Dec 31, 2024 | 41.34 Mn |
| Sep 30, 2024 | 39.34 Mn |
| Jun 30, 2024 | 37.77 Mn |
| Mar 31, 2024 | 36.23 Mn |
| Dec 31, 2023 | 36.95 Mn |
| Sep 30, 2023 | 35.24 Mn |
| Jun 30, 2023 | 32.10 Mn |
| Mar 31, 2023 | 31.07 Mn |
| Dec 31, 2022 | 31.95 Mn |
| Sep 30, 2022 | 31.17 Mn |
| Jun 30, 2022 | 29.65 Mn |
| Mar 31, 2022 | 29.63 Mn |
| Dec 31, 2021 | 31.98 Mn |
| Sep 30, 2021 | 32.01 Mn |
| Jun 30, 2021 | 31.02 Mn |
| Mar 31, 2021 | 32.45 Mn |